Laura Lynn Kovanda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Lynn Kovanda has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- William W. Hope
Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom
8 shared publications - Amit Desai
Astellas Pharma Global Development, Inc., Northbrook, USA
6 shared publications Christopher Lademacher
Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA
4 shared publications- David R. Andes
Department of Medicine, University of Wisconsin-Madison, Madison, USA
4 shared publications Amit V. Desai
Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA
3 shared publications- Nathan P. Wiederhold
Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio
3 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (6) , 51
Development of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations
Isavuconazonium sulfate is the water-soluble prodrug of the active triazole antifungal agent isavuconazole. Isavuconazonium sulfate is approved for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric and adult populations. In the present analysis, an isavuconazole physiologically-based pharmacokinetic (PBPK) model was built and verified in adult and pediatric populations using the Simcyp ® simulator. The verified pediatric model was then used to predict the magnitude of DDI risk in pediatric populations vs. adult populations. The simulations conducted were designed to match the observed clinical trials conducted in adults but with pediatric equivalent doses based on clinical guidelines. Based on the results of the analysis, isavuconazole DDI risk was similar between pediatric and adult populations. When the isavuconazole perpetrator DDI simulations were compared to adults, there was a trend of larger geometric mean (GM) AUC inf and C max ratios in patients 1 to < 3 years old receiving the 15 mg/kg dose. The GM AUC inf ratio in this study population ranged from 7 to 36% larger than predicted in the adult population. Based on the results of this analysis and literature reports, it is advisable to show greater caution when considering potential DDI in patients < 3-year-old, especially when receiving larger isavuconazonium sulfate doses. In addition, caution should be used in patients < 3 years-old when considering coadministration of isavuconazole with narrow therapeutic index medications such as digoxin and warfarin or medications with large variability in oral bioavailability such as midazolam.
- 22 September 2026
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (6) , 51
Open AccessDevelopment of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations
Isavuconazonium sulfate is the water-soluble prodrug of the active triazole antifungal agent isavuconazole. Isavuconazonium sulfate is approved for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric and adult populations. In the present analysis, an isavuconazole physiologically-based pharmacokinetic (PBPK) model was built and verified in adult and pediatric populations using the Simcyp ® simulator. The verified pediatric model was then used to predict the magnitude of DDI risk in pediatric populations vs. adult populations. The simulations conducted were designed to match the observed clinical trials conducted in adults but with pediatric equivalent doses based on clinical guidelines. Based on the results of the analysis, isavuconazole DDI risk was similar between pediatric and adult populations. When the isavuconazole perpetrator DDI simulations were compared to adults, there was a trend of larger geometric mean (GM) AUC inf and C max ratios in patients 1 to < 3 years old receiving the 15 mg/kg dose. The GM AUC inf ratio in this study population ranged from 7 to 36% larger than predicted in the adult population. Based on the results of this analysis and literature reports, it is advisable to show greater caution when considering potential DDI in patients < 3-year-old, especially when receiving larger isavuconazonium sulfate doses. In addition, caution should be used in patients < 3 years-old when considering coadministration of isavuconazole with narrow therapeutic index medications such as digoxin and warfarin or medications with large variability in oral bioavailability such as midazolam.
- Open Access
- 2 September 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (9)
Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children
Invasive fungal diseases (IFDs), including invasive aspergillosis (IA) and invasive mucormycosis (IM), occur primarily in immunocompromised and/or hospitalized patients and are associated with increased morbidity and mortality. Isavuconazole and posaconazole are triazole compounds approved for the treatment of IA/IM in adults and children, while voriconazole is approved for IA treatment only. All triazole compounds inhibit CYP3A, and both isavuconazole and posaconazole inhibit the transporter P-gp. Pediatric patients being treated for leukemia with vincristine frequently experience fungal infections, requiring treatment. Vincristine is metabolized by CYP3A4 and CYP3A5 and eliminated via P-gp transport. The risk of drug-drug interactions (DDIs) between vincristine and triazole compounds is known; however, the magnitude of risk has not been quantified. In the present analysis, physiologically based pharmacokinetic (PBPK) models were built for the triazoles and vincristine in a pediatric cancer population using the Simcyp simulator and were used to predict the change in vincristine exposure following coadministration with triazoles. Different age groups and CYP3A5 phenotypes were also explored. Modeling predicted that vincristine geometric mean AUC inf ratios in CYP3A5 poor metabolizers (PMs) ranged from 2.01- to 2.25-fold, 4.97- to 5.20-fold, and 1.43- to 1.53-fold with isavuconazole, posaconazole, and voriconazole, respectively. In CYP3A5 extensive metabolizers (EMs), vincristine AUC inf ratios ranged from 1.22- to 1.38-fold, 1.19- to 1.24-fold, and 1.05- to 1.07-fold for isavuconazole, posaconazole, and voriconazole, respectively. The model predicted vincristine AUC inf >100 ng·h/mL in CYP3A5 PM and <100 ng·h/mL in CYP3A5 EM; therefore, vincristine dose reduction may be required only in CYP3A5 null expressors.
- 2 September 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (9)
Open AccessPhysiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children
Invasive fungal diseases (IFDs), including invasive aspergillosis (IA) and invasive mucormycosis (IM), occur primarily in immunocompromised and/or hospitalized patients and are associated with increased morbidity and mortality. Isavuconazole and posaconazole are triazole compounds approved for the treatment of IA/IM in adults and children, while voriconazole is approved for IA treatment only. All triazole compounds inhibit CYP3A, and both isavuconazole and posaconazole inhibit the transporter P-gp. Pediatric patients being treated for leukemia with vincristine frequently experience fungal infections, requiring treatment. Vincristine is metabolized by CYP3A4 and CYP3A5 and eliminated via P-gp transport. The risk of drug-drug interactions (DDIs) between vincristine and triazole compounds is known; however, the magnitude of risk has not been quantified. In the present analysis, physiologically based pharmacokinetic (PBPK) models were built for the triazoles and vincristine in a pediatric cancer population using the Simcyp simulator and were used to predict the change in vincristine exposure following coadministration with triazoles. Different age groups and CYP3A5 phenotypes were also explored. Modeling predicted that vincristine geometric mean AUC inf ratios in CYP3A5 poor metabolizers (PMs) ranged from 2.01- to 2.25-fold, 4.97- to 5.20-fold, and 1.43- to 1.53-fold with isavuconazole, posaconazole, and voriconazole, respectively. In CYP3A5 extensive metabolizers (EMs), vincristine AUC inf ratios ranged from 1.22- to 1.38-fold, 1.19- to 1.24-fold, and 1.05- to 1.07-fold for isavuconazole, posaconazole, and voriconazole, respectively. The model predicted vincristine AUC inf >100 ng·h/mL in CYP3A5 PM and <100 ng·h/mL in CYP3A5 EM; therefore, vincristine dose reduction may be required only in CYP3A5 null expressors.
- Open Access
- 5 December 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (12) , e0048424
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial
Invasive aspergillosis (IA) and mucormycosis (IM) cause significant morbidity and mortality in immunocompromised and/or hospitalized patients. Isavuconazonium sulfate, a prodrug of the antifungal triazole isavuconazole, has been approved for treatment of IA and IM in adults; and was recently approved in children. This study describes the outcomes, safety, and pharmacokinetics of isavuconazole for the treatment of proven, probable, or possible IA or IM in children. In this phase 2, open-label, non-comparative study, patients aged 1 to <18 years with at least possible invasive mold disease were enrolled across 10 centers in the US, Spain, and Belgium from 2019 to 2022. Patients received 10 mg/kg isavuconazonium sulfate daily (maximum 372 mg; equivalent to 5.4 mg/kg or 200 mg isavuconazole) for up to 84 (IA) or 180 days (IM). Outcomes included rates of all-cause case fatality, overall response, treatment-emergent adverse events (TEAEs), and pharmacokinetics. Of 31 patients enrolled, 61.3% were 1–<12 years old; 58.1% had underlying hematologic malignancies. The successful overall response rate at the end of treatment was 54.8%. Day 42 all-cause case fatality was 6.5%; 93.5% experienced TEAEs, and two patients discontinued treatment due to drug-related TEAEs. Dosing at 10 mg/kg (maximum dose: 372 mg) met the pre-defined exposure threshold of above the 25th percentile for the area under the concentration-time curve (≥60 mg·h/L). Simulated doses of 15 mg/kg improved drug exposures in patients aged 1–<3 years. Isavuconazole was well tolerated in children, with exposure consistent with adult studies. Successful response was documented in 54.8% of patients. CLINICAL TRIALS: This study is registered at ClinicalTrials.gov as NCT03816176 .
- 5 December 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (12) , e0048424
Open AccessSafety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial
Invasive aspergillosis (IA) and mucormycosis (IM) cause significant morbidity and mortality in immunocompromised and/or hospitalized patients. Isavuconazonium sulfate, a prodrug of the antifungal triazole isavuconazole, has been approved for treatment of IA and IM in adults; and was recently approved in children. This study describes the outcomes, safety, and pharmacokinetics of isavuconazole for the treatment of proven, probable, or possible IA or IM in children. In this phase 2, open-label, non-comparative study, patients aged 1 to <18 years with at least possible invasive mold disease were enrolled across 10 centers in the US, Spain, and Belgium from 2019 to 2022. Patients received 10 mg/kg isavuconazonium sulfate daily (maximum 372 mg; equivalent to 5.4 mg/kg or 200 mg isavuconazole) for up to 84 (IA) or 180 days (IM). Outcomes included rates of all-cause case fatality, overall response, treatment-emergent adverse events (TEAEs), and pharmacokinetics. Of 31 patients enrolled, 61.3% were 1–<12 years old; 58.1% had underlying hematologic malignancies. The successful overall response rate at the end of treatment was 54.8%. Day 42 all-cause case fatality was 6.5%; 93.5% experienced TEAEs, and two patients discontinued treatment due to drug-related TEAEs. Dosing at 10 mg/kg (maximum dose: 372 mg) met the pre-defined exposure threshold of above the 25th percentile for the area under the concentration-time curve (≥60 mg·h/L). Simulated doses of 15 mg/kg improved drug exposures in patients aged 1–<3 years. Isavuconazole was well tolerated in children, with exposure consistent with adult studies. Successful response was documented in 54.8% of patients. CLINICAL TRIALS: This study is registered at ClinicalTrials.gov as NCT03816176 .
- Open Access
- 25 April 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-11
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
Isavuconazole is a triazole with broad-spectrum antifungal activity. In this post-hoc analysis of two prospective clinical trials (VITAL and SECURE), the safety and efficacy of isavuconazole in patients aged ≥ 65 years with invasive fungal diseases were evaluated. Patients were divided into two subgroups (≥ 65 and < 65 years). Adverse events (AEs); all-cause mortality; and overall, clinical, mycological, and radiological response were assessed. A total of 155 patients ≥ 65 years were enrolled in both trials. Most patients reported AEs. In the isavuconazole arm of both studies, serious AEs (SAEs) were greater in patients ≥ 65 versus < 65 years: 76.7% versus 56.9% (VITAL); 61.9% versus 49.0% (SECURE). In SECURE, SAE rates were similar in the ≥ 65 years subgroup of both treatment arms (61.9% vs 58.1%), while in the < 65 years subgroup the SAE rate was lower in the isavuconazole arm (49.0% vs 57.4%). In VITAL, all-cause mortality through day 42 (30.0% vs 13.8%) was higher, and overall response at end of treatment (27.6% vs 46.8%) was lower in patients ≥ 65 years versus < 65 years. In SECURE, all-cause mortality was similar between both subgroups, and isavuconazole (20.6% vs 17.9%) and voriconazole (22.6% vs 19.4%) treatment arms. The overall response was lower in the ≥ 65 years than the < 65 years subgroup in the isavuconazole (23.7% vs 39.0%) and voriconazole (32.0% vs 37.5%) arms. The safety and efficacy of isavuconazole were better in patients < 65 versus ≥ 65 years, and the safety profile was more favorable than that of voriconazole in both subgroups.Clinicaltrials.gov identifier NCT00634049 and NCT00412893.
- 25 April 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-11
Open AccessPost-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
Isavuconazole is a triazole with broad-spectrum antifungal activity. In this post-hoc analysis of two prospective clinical trials (VITAL and SECURE), the safety and efficacy of isavuconazole in patients aged ≥ 65 years with invasive fungal diseases were evaluated. Patients were divided into two subgroups (≥ 65 and < 65 years). Adverse events (AEs); all-cause mortality; and overall, clinical, mycological, and radiological response were assessed. A total of 155 patients ≥ 65 years were enrolled in both trials. Most patients reported AEs. In the isavuconazole arm of both studies, serious AEs (SAEs) were greater in patients ≥ 65 versus < 65 years: 76.7% versus 56.9% (VITAL); 61.9% versus 49.0% (SECURE). In SECURE, SAE rates were similar in the ≥ 65 years subgroup of both treatment arms (61.9% vs 58.1%), while in the < 65 years subgroup the SAE rate was lower in the isavuconazole arm (49.0% vs 57.4%). In VITAL, all-cause mortality through day 42 (30.0% vs 13.8%) was higher, and overall response at end of treatment (27.6% vs 46.8%) was lower in patients ≥ 65 years versus < 65 years. In SECURE, all-cause mortality was similar between both subgroups, and isavuconazole (20.6% vs 17.9%) and voriconazole (22.6% vs 19.4%) treatment arms. The overall response was lower in the ≥ 65 years than the < 65 years subgroup in the isavuconazole (23.7% vs 39.0%) and voriconazole (32.0% vs 37.5%) arms. The safety and efficacy of isavuconazole were better in patients < 65 versus ≥ 65 years, and the safety profile was more favorable than that of voriconazole in both subgroups.Clinicaltrials.gov identifier NCT00634049 and NCT00412893.
- Open Access
- 22 March 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (3) , 472
Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies
Background: Neonates may require higher doses of micafungin than adults to reach the therapeutic effect for increased plasma clearance. Only poor and inconclusive data are available still now to support this hypothesis, especially with regard to central nervous system micafungin concentrations. To assess the pharmacokinetics of increased doses (8 to 15 mg/kg/day) of micafungin in preterm and term neonates with invasive candidiasis and to complete previously presented results, we analyzed the pharmacokinetic data on a total of 53 newborns treated with micafungin, whereby 3 of them had Candida meningitis and hydrocephalus. Methods: Fifty-three neonates with systemic candidiasis, three of them with meningitis, were treated for at least 14 days with intravenous micafungin (Mycamine®) at a dosage ranging from 8 to 15 mg/kg/day. Plasma and cerebrospinal fluid (CSF) concentrations of micafungin were measured before the drug administration and at 1, 2, and 8 h after the end of the infusion using high-performance liquid chromatography (HPLC). Systemic exposure was assessed according to AUC0–24, plasma clearance (CL), and half-life measured in 52/53 patients, divided by chronological age. Results and conclusions: The mean micafungin clearance is higher in neonates than in older infants (0.036 L/h/kg before 28 days of life versus 0.028 L/h/kg after 120 days). The drug half-life is shorter in neonates than in older patients (13.5 h before 28 days of life versus 14.4 h after 120 days). With doses ranging between 8 and 15 mg/kg/day, micafungin crosses the blood–brain barrier reaching therapeutic levels in CSF.
- 22 March 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (3) , 472
Open AccessPlasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies
Background: Neonates may require higher doses of micafungin than adults to reach the therapeutic effect for increased plasma clearance. Only poor and inconclusive data are available still now to support this hypothesis, especially with regard to central nervous system micafungin concentrations. To assess the pharmacokinetics of increased doses (8 to 15 mg/kg/day) of micafungin in preterm and term neonates with invasive candidiasis and to complete previously presented results, we analyzed the pharmacokinetic data on a total of 53 newborns treated with micafungin, whereby 3 of them had Candida meningitis and hydrocephalus. Methods: Fifty-three neonates with systemic candidiasis, three of them with meningitis, were treated for at least 14 days with intravenous micafungin (Mycamine®) at a dosage ranging from 8 to 15 mg/kg/day. Plasma and cerebrospinal fluid (CSF) concentrations of micafungin were measured before the drug administration and at 1, 2, and 8 h after the end of the infusion using high-performance liquid chromatography (HPLC). Systemic exposure was assessed according to AUC0–24, plasma clearance (CL), and half-life measured in 52/53 patients, divided by chronological age. Results and conclusions: The mean micafungin clearance is higher in neonates than in older infants (0.036 L/h/kg before 28 days of life versus 0.028 L/h/kg after 120 days). The drug half-life is shorter in neonates than in older patients (13.5 h before 28 days of life versus 14.4 h after 120 days). With doses ranging between 8 and 15 mg/kg/day, micafungin crosses the blood–brain barrier reaching therapeutic levels in CSF.
- Open Access
- 16 July 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (8)
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Isavuconazole, administered as the water-soluble prodrug isavuconazonium sulfate, is a new triazole agent used to treat invasive fungal infections. This phase 1 study evaluated the pharmacokinetics (PK), safety, and tolerability of isavuconazole in 46 immunocompromised pediatric patients, stratified by age (1 to <6 [intravenous (i.v.) only], 6 to <12, and 12 to <18 years), receiving 10 mg/kg body weight (maximum, 372 mg) isavuconazonium sulfate either i.v. or orally.
- 16 July 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (8)
Open AccessSafety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Isavuconazole, administered as the water-soluble prodrug isavuconazonium sulfate, is a new triazole agent used to treat invasive fungal infections. This phase 1 study evaluated the pharmacokinetics (PK), safety, and tolerability of isavuconazole in 46 immunocompromised pediatric patients, stratified by age (1 to <6 [intravenous (i.v.) only], 6 to <12, and 12 to <18 years), receiving 10 mg/kg body weight (maximum, 372 mg) isavuconazonium sulfate either i.v. or orally.
- Open Access
- 18 May 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (6)
Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis
Coccidioides spp. are important pathogens in endemic regions and new treatment options are needed. Isavuconazonium sulfate (ISAVUSULF) and fluconazole (FLU) were evaluated in experimental disseminated coccidioidomycosis to characterize drug exposures associated with efficacy. Macrobroth dilution was performed on Coccidioides isolates to measure minimal effective concentrations (MEC) and minimal fungicidal concentrations (MFC). Mice were inoculated with Coccidioides posadasii (Silveira strain). Treatment started 4 days post-inoculation. (Model 1) Mice were treated 19 days plus 30-day off-therapy observation, measuring survival through day 49 and residual fungal burden. Treatments included ISAVUSULF (prodrug: 186, 279, or 372 mg/kg twice-daily), FLU (20 or 100 mg/kg once-daily), and untreated. Model 2 included 7-day treatment with ISAVUSULF (prodrug: 74.4, 111.6, or 148.8 mg/kg twice-daily), FLU (20 or 100 mg/kg once-daily), and untreated. Serial plasma and tissues samples were obtained for PK and fungal burden measurement, respectively. MEC50 were 0.39 mg/L (ISAV) and 12.5 mg/L (FLU). Treatment with ISAVUSULF186 or both FLU doses resulted in higher survival compared to untreated. Treatment with ISAVUSULF 186 or 279 mg/kg twice-daily or FLU 100 mg/kg reduced fungal burden in all organs (Model 1). In model 2, >1 log10 CFU/organ reduction was demonstrated, with ISAV AUCs achieved with 111.6 mg/kg twice-daily (56.8 mg•h/L), in the spleen and liver. FLU AUCs, 100 and 500 mg•h/L, for 20 and 100 mg/kg doses, respectively, resulted in >1 log10 CFU/organ mean reduction in all organs. ISAVUSULF and FLU improved survival and reduced fungal burden. Increasing plasma drug exposures resulted in decreases in fungal burden.
- 18 May 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (6)
Open AccessEfficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis
Coccidioides spp. are important pathogens in endemic regions and new treatment options are needed. Isavuconazonium sulfate (ISAVUSULF) and fluconazole (FLU) were evaluated in experimental disseminated coccidioidomycosis to characterize drug exposures associated with efficacy. Macrobroth dilution was performed on Coccidioides isolates to measure minimal effective concentrations (MEC) and minimal fungicidal concentrations (MFC). Mice were inoculated with Coccidioides posadasii (Silveira strain). Treatment started 4 days post-inoculation. (Model 1) Mice were treated 19 days plus 30-day off-therapy observation, measuring survival through day 49 and residual fungal burden. Treatments included ISAVUSULF (prodrug: 186, 279, or 372 mg/kg twice-daily), FLU (20 or 100 mg/kg once-daily), and untreated. Model 2 included 7-day treatment with ISAVUSULF (prodrug: 74.4, 111.6, or 148.8 mg/kg twice-daily), FLU (20 or 100 mg/kg once-daily), and untreated. Serial plasma and tissues samples were obtained for PK and fungal burden measurement, respectively. MEC50 were 0.39 mg/L (ISAV) and 12.5 mg/L (FLU). Treatment with ISAVUSULF186 or both FLU doses resulted in higher survival compared to untreated. Treatment with ISAVUSULF 186 or 279 mg/kg twice-daily or FLU 100 mg/kg reduced fungal burden in all organs (Model 1). In model 2, >1 log10 CFU/organ reduction was demonstrated, with ISAV AUCs achieved with 111.6 mg/kg twice-daily (56.8 mg•h/L), in the spleen and liver. FLU AUCs, 100 and 500 mg•h/L, for 20 and 100 mg/kg doses, respectively, resulted in >1 log10 CFU/organ mean reduction in all organs. ISAVUSULF and FLU improved survival and reduced fungal burden. Increasing plasma drug exposures resulted in decreases in fungal burden.
- Open Access
- 1 September 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (9)
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
Cryptococcus spp., important fungal pathogens, are the leading cause of fungus-related mortality in human immunodeficiency virus-infected patients, and new therapeutic options are desperately needed. Isavuconazonium sulfate, a newer triazole antifungal agent, was studied to characterize the exposure-response relationship in a rabbit model of cryptococcal meningoencephalitis. Rabbits treated with isavuconazonium sulfate were compared with those treated with fluconazole and untreated controls.
- 1 September 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (9)
Open AccessPharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
Cryptococcus spp., important fungal pathogens, are the leading cause of fungus-related mortality in human immunodeficiency virus-infected patients, and new therapeutic options are desperately needed. Isavuconazonium sulfate, a newer triazole antifungal agent, was studied to characterize the exposure-response relationship in a rabbit model of cryptococcal meningoencephalitis. Rabbits treated with isavuconazonium sulfate were compared with those treated with fluconazole and untreated controls.
- 1 June 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (6)
Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects
VL-2397, a novel, systemic antifungal agent, has potent in vitro and in vivo fungicidal activity against Aspergillus species. Plasma concentrations from a phase 1 study were used to construct a population pharmacokinetic (PPK) model for VL-2397.
- 1 June 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (6)
Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects
VL-2397, a novel, systemic antifungal agent, has potent in vitro and in vivo fungicidal activity against Aspergillus species. Plasma concentrations from a phase 1 study were used to construct a population pharmacokinetic (PPK) model for VL-2397.
- Open Access
- 1 January 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (1) , e01634-18
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.
- 1 January 2019
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (1) , e01634-18
Open AccessOutcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.